NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 11.50 against a street estimate of 13.16 — a miss of 12.6%.
with an average price target of ₹2,128.70.
MIXED Sun Pharma delivered strong revenue and India growth, but U.S. Ilumya slowed, margins declined year-on-year, and FY27 guidance remains unchanged despite first-half double-digit growth. Q2 FY27 India was the strongest reported region; U.S. performance was pressured by lenalidomide erosion and slower Ilumya growth. Analysts focused on Ilumya’s slowdown, psoriatic arthritis potential, R&D phasing, Organon financing and regional growth. Management emphasized execution remedies, existing sales-force capacity, unchanged guidance and second-half R&D acceleration. 2026-10-30…
Full summary in the app.
| Holder | Stake |
|---|---|
| Life Insurance Corporation of India | 5.32% |
| ICICI Prudential Value Fund | 3.21% |
| SBI Nifty 50 ETF | 2.82% |
| NPS Trust- A/C HDFC Pension Fund Management Limited Scheme E - Tier I | 1.96% |
| Nippon Life India Trustee Ltd-A/C Nippon India ETF Nifty 50 Bees | 1.32% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call SUN PHARMACEUTICAL INDUSTRIES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Q1 FY27 consolidated sales: INR 1,51,836 million, up 10.1% year-over-year | 2026-08-06 |
| Investor presentation · Q1 FY27 SUN PHARMACEUTICAL INDUSTRIES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Gross Sales: Rs 582,201 million (12% YoY growth) • EBITDA: Rs 177,3 | 2026-07-07 |
| Annual report FY2026 SUN PHARMACEUTICAL INDUSTRIES LIMITED – FY26 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Total consolidated revenues: ₹584.6 billion (FY26), up 11.9% f | 2026-07-06 |
| Q4 FY26 earnings call SUN PHARMACEUTICAL INDUSTRIES LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 sales: INR 145,598 million, up 13.6% year-on-year • Full year FY2 | 2026-05-29 |
| Quarterly results · Q4 FY26 SUN PHARMACEUTICAL INDUSTRIES LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations (FY 2025-26): ₹207,546.4 Million (down from ₹22 | 2026-05-22 |
| Investor presentation · Q4 FY26 SUN PHARMACEUTICAL INDUSTRIES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY25 Revenue: $6.2 billion • FY25 EBITDA: $1.8 billion • Cash on Hand (F | 2026-04-27 |
| Investor presentation · Q3 FY26 SUN PHARMACEUTICAL INDUSTRIES LIMITED INVESTOR SUMMARY – FEBRUARY 2026 --- HEADLINE NUMBERS • FY25 Gross Sales: Rs 520,412 mn (9% YoY growth) • FY2 | 2026-02-24 |
| Q3 FY26 earnings call SUN PHARMACEUTICAL INDUSTRIES LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 consolidated sales: Rs.1,54,691 million, up 15.1% YoY (14.7% excl | 2026-02-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹5 / share ex-date Jul 7, 2026 | 2026-07-07 |
| Dividend | ₹11 / share ex-date Feb 5, 2026 | 2026-02-05 |
| Announcement | Date |
|---|---|
| Organon shareholder approval received for proposed acquisition Sun Pharmaceutical Industries Limited announced that Organon & Co.'s shareholders have approved the proposed acquisition by Sun Pharma. This is a major milestone in the deal process, clearin | 2026-07-24 |
| Acquisition of Innovcare Lifesciences Private Limited Acquisition of Innovcare Lifesciences Private Limited | 2026-06-20 |
| Investor call scheduled to discuss acquisition of Organon & Co. Sun Pharmaceutical Industries announced plans to acquire Organon & Co., as disclosed in a press release dated April 27, 2026. The company informed the stock exchange about an investor call s | 2026-04-27 |
| Definitive agreement to acquire Organon announced Sun Pharmaceutical Industries Limited has informed the Exchange about Definitive Agreement to Acquire Organon | 2026-04-27 |
| Interim dividend of 11 per equity share declared Sun Pharmaceutical Industries Limited announced that its Board of Directors declared an interim dividend of ₹11 per equity share at a meeting held on January 31, 2026. Key Details: - Divide | 2026-01-31 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sun Pharmaceutical Industries Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.